Pharmaceuticals

Revenue of the Farber’s Disease Market Predicted to Achieve $2.61 Billion by 2030, Driven by 5.6% CAGR

February 16, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the farber’s disease market from 2026–2035 with trusted insights from The Business Research Company

Starting from its 2026 valuation, what market size is the Farber’s Disease Market expected to reach by 2030?

The farber’s disease market has experienced substantial expansion in recent years. It is anticipated to increase from $1.98 billion in 2025 to $2.1 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 5.9%. The expansion observed in prior periods can be attributed to elements such as rare disease identification, pediatric genetic testing, the implementation of supportive care protocols, hospital specialization, and dedicated research funding.

The farber’s disease market size is projected to experience substantial expansion in the coming years. It is predicted to reach $2.61 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 5.6%. Factors contributing to this growth during the forecast period include the development of gene therapy pipelines, incentives for orphan drugs, initiatives for early diagnosis, rare disease registries, and sophisticated genetic tools. Key trends anticipated in the forecast period encompass a heightened emphasis on rare pediatric disorders, the broadening of gene therapy research, increasing uptake of supportive care, the adoption of multidisciplinary treatment strategies, and advancements in genetic diagnostics.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24533&type=smp

What Drivers Are Driving Adoption Within The Farber’s Disease Market?

The farber’s disease market is anticipated to expand due to the increasing occurrence of rare genetic diseases. These inherited disorders, which stem from DNA mutations, impact a small fraction of the population. Their rising prevalence is attributed to better diagnostic tools that allow for earlier and more precise detection of conditions often previously missed or misdiagnosed. Farber’s disease contributes to addressing this increasing prevalence by providing a framework for creating targeted therapies and advancing enzyme replacement research for extremely rare conditions. As an illustration, in February 2023, the European Commission (EC), a Belgium-based government entity, reported that up to 36 million individuals in the European Union are affected by a rare disease, with over 6,000 unique rare diseases in the EU, and approximately 80% of these have a genetic basis. Consequently, the increasing incidence of rare genetic diseases is fueling the expansion of the farber’s disease market. Future expansion of the farber’s disease market is predicted due to rising investments in clinical trials. These human research studies assess the safety, efficacy, and results of various medical interventions like drugs or treatments. The surge in clinical trial funding is a response to the escalating demand for new therapies, spurred by advancements in medical science, personalized medicine, and the critical requirement to fulfill unaddressed healthcare demands. Farber’s disease plays a role in justifying this increased investment by underscoring the vital need for research into rare and neglected genetic conditions. For example, in October 2024, Citeline, a US-based pharma intelligence solutions provider, reported that TrialTrove identified 9,959 Phase I–III clinical trials commencing in 2024 to investigate at least one drug, marking a 9.4% rise from 2023. Thus, the growing investment in clinical trials is stimulating the farber’s disease market’s growth.

What Segments Are Included Within The Farber’s Disease Market?

The farber’s disease market covered in this report is segmented –

1) By Type Of Farber’s Disease: Classical Farber’s Disease, Non-Classical Farber’s Disease

2) By Treatment: Enzyme Replacement Therapy, Symptomatic Treatment, Gene Therapy, Bone Marrow Transplant, Supportive Care

3) By Clinical Symptoms: Joint Involvement And Deformities, Hearing Loss, Respiratory Distress, Dermatological Manifestations

4) By End-User: Hospitals, Specialty Clinics, Diagnostic Centers, Other End-Users

Subsegments:

1) By Classical Farber’s Disease: Type 1 Severe Infantile Form, Type 2 Intermediate Childhood Form, Type 3 Juvenile-Onset Form

2) By Non-Classical Farber’s Disease: Type 4 Neurological Predominant Form, Type 5 Visceral Predominant Form, Type 6 Cardiopulmonary Involvement Form

Who Are The Core Companies Influencing Trends In The Farber’s Disease Market?

Major companies operating in the farber’s disease market are National Institutes of Health (NIH), U.S. National Institute of Neurological Disorders and Stroke (NINDS), Mount Sinai Icahn School of Medicine, Cincinnati Children’s Hospital Medical Center, University of Pennsylvania Gene Therapy Program, Seattle Children’s Research Institute, Genethon (AFM-Téléthon), Sarepta Therapeutics Inc., REGENXBIO Inc., Abeona Therapeutics Inc., Rocket Pharmaceuticals Inc., Passage Bio Inc., Spark Therapeutics Inc., Takeda Rare Disease Research, Orchard Therapeutics plc, Avrobio Inc., bluebird bio Inc., JCR Pharmaceuticals Co. Ltd., Protalix BioTherapeutics Inc., Ultragenyx Pharmaceutical Inc., BioMarin Pharmaceutical Inc., Amicus Therapeutics Inc.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/farbers-disease-global-market-report

Which Regions Are Projected To Dominate The Farber’s Disease Market In The Coming Years?

North America was the largest region in the farber’s disease market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the farber’s disease market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Farber’s Disease Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=24533&type=smp

Browse Through More Reports Similar to the Global Farber’s Disease Market 2026, By The Business Research Company

Rare Disease Diagnostics Market Report 2026

https://www.thebusinessresearchcompany.com/report/rare-disease-diagnostics-global-market-report

Rare Diseases Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/rare-diseases-treatment-global-market-report

Rare Kidney Diseases Market Report 2026

https://www.thebusinessresearchcompany.com/report/rare-kidney-diseases-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795